Assessment of transfer entropy is useful for network analysis of cell signaling network providing information on the network topology and action points of genetic mutations and drug effect, thus will ...

Mutations in the RAS-RAF-MEK-ERK pathway that drive many forms of human malignancies. In particular, the serine/threonine kinase BRAF is mutated in ~8% of all cancers. Targeted inhibitors have been ...

The laboratory is studying small molecules that selectively inhibit the components of RAS-RAF-MEK-ERK and PI3K-AKT-mTOR pathways. These compounds are being used as reagents to define the role of these ...

The company's pipeline includes IMM-6-415, another deep cyclic inhibitor of MEK, which is also undergoing a Phase 1/2a trial in patients with advanced solid tumors harboring RAS or RAF mutations.

The review explores strategies to overcome this resistance, focusing on targeting downstream molecules within the RAS-RAF-MEK-ERK and PI3K-AKT-mTOR pathways. Furthermore, the study explores the ...

Verastem Oncology is currently conducting clinical trials with avutometinib with and without defactinib in RAS/MAPK-driven tumors as part of its Raf And Mek Program or RAMP. Verastem is currently ...